Table 2.
Mbarara, Uganda (MBA, Enrolled 2005–2010, ntotal=491)
| Posttherapy virologic suppressiona throughout therapy (n=6) | Virologic failurea (n=4) | Initially suppresseda, but rebounded and stayed failedc (n=3) | No follow-up (n=2) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UARTO patient ID (MBA) | 1323 | 1118 | 1161 | 1347 | 1466 | 1467 | 1057 | 1202 | 1300 | 1309 | 1450 | 1294 | 1470 | 1130 | 1306 |
| Baseline characteristics | |||||||||||||||
| Gender | F | F | F | F | F | F | F | M | F | F | F | F | F | F | F |
| Age | 31 | 22 | 33 | 31 | 22 | 25 | 23 | 33 | 22 | 27 | 37 | 25 | 30 | 37 | 28 |
| Baseline log VL | 4.9 | 5.7 | 3.9 | 3.6 | 5.3 | 5.9 | 5.4 | 5.0 | 4.9 | 3.9 | 3.4 | 5.9 | 4.2 | 3.9 | 3.6 |
| Baseline CD4 count | 160 | 271 | 316 | 226 | 159 | 30 | 7 | 97 | 426 | 174 | 198 | 7 | 12 | 36 | 14 |
| Pregnant within last 12 months? | No | Blank | No | No | No | No | Yes | — | No | No | Yes | No | No | No | No |
| Viral subtype | AE | D | D | D | A | D | D | A | A | A | A | D | D | A | D |
| Pretherapy plasma resistance profiles | |||||||||||||||
| NNRTIb | P225H | K103K/N | — | — | K103N | — | Y181C/Y | K103K/N, Y181C/Y | K101E/K | K103N | K103N | K103K/N/R/S | K103N | K103K/N,G190A | — |
| NRTIb | — | — | K219K/Q | M184V | — | K70K/E | T69A/D/N/T | — | — | M184V | — | — | — | — | T69A/D/N/T |
| PIb | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| HPLC-MS/MS drug level | ND | NVP (2.6 μg/ml) | ND | ND | ND | ND | ND | ND | ND | NVP (5.9 μg/ml) | ND | ND | NVP (2.1 μg/ml) | ND | ND |
| Treatment and virologic consequences | |||||||||||||||
| NNRTI | NVP | NVPc | NVP | EFV | NVPc | NVP | NVPc | NVPc | NVPc | NVPc | NVPc | NVPc | NVPc | — | — |
| NRTI | 3TC/AZT | 3TC/d4T | 3TC/AZTc | 3TCc/AZT | 3TC/AZT | 3TC/AZTc | 3TCc/d4Tc | 3TC/d4T | 3TC/AZT | 3TCc/AZT | 3TC/AZT | 3TC/AZT | 3TC/AZT | — | — |
| PI | — | — | — | — | — | — | — | — | — | LPV | — | — | — | — | — |
| Given TDR profile, was initial regimen appropriate? | Yes | No | No | No | No | No | No | No | No | No | No | No | No | — | — |
| Duration of continuously suppressed VL (days) | 1745 | 684 | 2184 | 1857 | 343 | 1425 | — | — | — | — | 416 | 754 | 168 | — | — |
| Duration of continuously unsuppressed VL without change in “bad” regimen (days) | — | — | — | — | — | — | 835 | 327 | 628 | 252 | 1015 | 1058 | 170 | — | — |
| Regimen modification (days posttherapy, new regimen) | — | — | — | 169, NVP/3TC/AZT | — | — | 932, LPV/TDF/FTC | 415, LPV/TDF/FTC | — | 337, LPV/TDF/FTC | — | — | — | — | — |
| Log VL at study cutoff | ND | ND | ND | ND | ND | ND | ND | ND | log 3 | ND | log 2 | log 4 | log 4 | — | — |
a
Virologic suppression was defined as ≤400 copies HIV-RNA/ml and detectable viral load and virologic failure were defined as >400 copies HIV-RNA/ml.
b
Transmitted drug resistance (TDR) mutations were defined by the WHO 2009 surveillance mutation list.
c
Drugs in initial regimen that were contraindicated with pretherapy resistance profiles.
Detailed baseline characteristics, resistance profiles, treatment history, and virologic consequences of the 15 cases of WHO-defined transmitted drug resistance (TDR) reported in this study.
M, male; AZT, zidovudine; LPV, lopinavir; TDF, tenofovir; FTC, emtricitabine; for other abbreviations see Table 1.